Gradion Hip TCR System
Phase 1- Indications
- Hip osteoarthritis
Company intelligence / Profile preview
Biomimedica
Berkeley, California, United Statespmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Biomimedica developed a proprietary synthetic cartilage platform, GRADION TCR, aimed at earlier intervention and joint repair in osteoarthritis. The company raised over $11.9 million in Series B funding by 2012 and spun out from Stanford University. Its technology was designed to address the unmet need for durable, biocompatible joint implants but there is no evidence of commercial products or late-stage trials as of the latest public information[1][5].
- Therapeutic areas
- Rheumatology
- Modalities
- DeviceBiologic (synthetic cartilage/biomaterial)
- Industry
- Implantable Medical Devices
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Biomimedica.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Biomimedica.